<DOC>
	<DOCNO>NCT00431340</DOCNO>
	<brief_summary>This open-label study assess anti-tumor activity safety belinostat combination bortezomib ( Velcade® ) multiple myeloma patient refractory relapse least one prior bortezomib-containing regimen . Subjects administer PXD101 bortezomib day : i.e . day 1 , 4 , 8 , 11 3-week cycle , 8 cycle .</brief_summary>
	<brief_title>A Phase II Study Belinostat Combination With Bortezomib Patients With Relapsed , Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosis multiple myeloma . Status refractory relapse least one prior bortezomibcontaining regimen . Progressive disease . Age &gt; = 18 year . Karnofsky performance status &gt; = 60 % Acceptable liver function : Bilirubin = &lt; 1.5 x ULN ( upper limit normal ) Aspartate transaminase ( AST ) alanine transaminase ( ALT ) = &lt; 3 x ULN Acceptable hematologic status : Absolute Neutrophil Count ( ANC ) &gt; = 1.5 x 109/L Platelet count &gt; = 100 x 109/L Hemoglobin &gt; = 9 g/dL Coagulation status PTINR/PTT = &lt; 1.5 x ULN therapeutic range anticoagulation therapy . ( PTINR/PTT= prothrombin international normalized ratio / prothrombin time ) Serum potassium within normal range . Estimated life expectancy great 3 month . Signed , write IRB ( institutional Review Board ) approve informed consent . Nonsecretory multiple myeloma symptomatic amyloidosis . Hypersensitivity bortezomib , boron , mannitol . Less 4 week since prior chemotherapy , radiotherapy , endocrine therapy , immunotherapy , except disease rapidly progress . Less 4 week since prior use investigational agent . Serious concomitant systemic disorder ( e.g . active infection ) . Significant cardiovascular disease . Marked baseline prolongation QT/QTc ( correct QT interval ) interval . Central nervous system disorder require neuroleptic / anticonvulsant . Peripheral sensory neuropathy ≥ Grade 2 Renal insufficiency define creatinine clearance &lt; 30 ml/min . Nonwillingness use effective contraceptive method patient childbearing age / potential . Pregnant breastfeed woman . Known HIV positivity . Prior treatment belinostat ( PXD101 ) , HDAC ( histone deacetylase ) inhibitor . Altered mental status precludes understand Informed Consent Document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>myeloma</keyword>
	<keyword>plasma cell myeloma</keyword>
	<keyword>bone marrow cancer</keyword>
	<keyword>myelomatosis</keyword>
	<keyword>Kahler 's disease</keyword>
	<keyword>PXD101</keyword>
	<keyword>belinostat</keyword>
	<keyword>bortezomib</keyword>
</DOC>